William Blair analyst Myles Minter has reiterated their bullish stance on VTGN stock, giving a Buy rating on November 3.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of VistaGen Therapeutics. The company is advancing its fasedienol treatment for social anxiety disorder, with pivotal data from the PALISADE-3 and PALISADE-4 studies expected soon. These studies are crucial for confirming the positive results from earlier trials and could lead to a New Drug Application submission in the first half of 2026.
Minter notes that despite regulatory uncertainties, VistaGen’s management is confident in the approval process, and the company is financially prepared to support these efforts. The large potential market of over 30 million patients in the U.S. alone presents a significant opportunity for fasedienol. Given these factors, Minter believes that VistaGen’s stock offers an attractive risk/reward profile, justifying the Buy rating.
In another report released on November 3, Maxim Group also maintained a Buy rating on the stock with a $12.00 price target.